Skip to search formSkip to main contentSkip to account menu

simtuzumab

A humanized monoclonal antibody against lysyl oxidase-like 2 (LOXL2), with potential antineoplastic activity. Anti-LOXL2 monoclonal antibody GS 6624… 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (2)

AB0024GS-6624

Broader (1)

Antibodies, Monoclonal, Humanized
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
LOXL2—A New Target in Antifibrogenic Therapy?
The concept of liver fibrosis and cirrhosis being static and therefore irreversible is outdated. Indeed, both human and animal… 
Review
2018
Review
2018
Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
2018
2018
Is This the Last Requiem for Simtuzumab?
In modern hepatology we sing the song for the advent of effective antifibrotic drugs for decades recalling the line of a… 
Highly Cited
2017
Highly Cited
2017
Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial.
2017
2017
A phase 2 study of simtuzumab in patients with primary, post‐polycythaemia vera or post‐essential thrombocythaemia myelofibrosis
Simtuzumab, a monoclonal antibody inhibitor of extracellular matrix enzyme lysyl oxidase‐like‐2, showed preclinical promise and… 
Review
2017
Review
2017
Clinical trial research in focus: why do so many clinical trials fail in IPF?
Review
2016
Review
2016
Novel Pharmacotherapy Options for NASH
While simple to recommend, diet and lifestyle measures as a first-line therapy for nonalcoholic steatohepatitis (NASH) are hardly… 
Review
2015
Review
2015
Non-alcoholic fatty liver disease in 2015.
There is worldwide epidemic of non-alcoholic fatty liver disease (NAFLD). NAFLD is a clinical entity related to metabolic… 
Review
2015
Review
2015
Therapy of Primary Sclerosing Cholangitis - Today and Tomorrow
Primary sclerosing cholangitis (PSC) represents a fibro-obliterative bile duct disease with unpredictable individual clinical… 
2014
2014
618PDA PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF SIMTUZUMAB OR PLACEBO IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PANCREATIC ADENOCARCINOMA.
ABSTRACT Aim: Simtuzumab (SIM) is a humanized antibody that inhibits lysyl oxidase-like molecule 2 (LOXL2), an extracellular… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)